454 related articles for article (PubMed ID: 33387367)
1. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study.
Agulló L; Aguado I; Muriel J; Margarit C; Gómez A; Escorial M; Sánchez A; Fernández A; Peiró AM
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445931
[TBL] [Abstract][Full Text] [Related]
3. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
4. Pain polymorphisms and opioids: An evidence based review.
Vieira CMP; Fragoso RM; Pereira D; Medeiros R
Mol Med Rep; 2019 Mar; 19(3):1423-1434. PubMed ID: 30592275
[TBL] [Abstract][Full Text] [Related]
5. A logistic equation to determine the validity of tramadol from related gene polymorphisms and psychological factors.
Zhao Q; Sun J; Tao Y; Wang S; Jiang C; Zhu Y; Yu F; Zhu J
Pharmacogenomics; 2014 Mar; 15(4):487-95. PubMed ID: 24624916
[TBL] [Abstract][Full Text] [Related]
6. Reviewing pharmacogenetics to advance precision medicine for opioids.
Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
[TBL] [Abstract][Full Text] [Related]
7. Clinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approach.
Escorial M; Muriel J; Agulló L; Zandonai T; Margarit C; Morales D; Peiró AM
Minerva Anestesiol; 2024 May; 90(5):386-396. PubMed ID: 38619184
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
[TBL] [Abstract][Full Text] [Related]
9. The Role of Pharmacogenomics in Opioid Prescribing.
Wong AK; Somogyi AA; Rubio J; Philip J
Curr Treat Options Oncol; 2022 Oct; 23(10):1353-1369. PubMed ID: 36001223
[TBL] [Abstract][Full Text] [Related]
10. Predicted activity of UGT2B7, ABCB1, OPRM1, and COMT using full-gene haplotypes and their association with the CYP2D6-inferred metabolizer phenotype.
Wendt FR; Sajantila A; Budowle B
Forensic Sci Int Genet; 2018 Mar; 33():48-58. PubMed ID: 29190510
[TBL] [Abstract][Full Text] [Related]
11. The associations between OPRM 1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation.
Henker RA; Lewis A; Dai F; Lariviere WR; Meng L; Gruen GS; Sereika SM; Pape H; Tarkin IS; Gowda I; Conley YP
Biol Res Nurs; 2013 Jul; 15(3):309-17. PubMed ID: 22718527
[TBL] [Abstract][Full Text] [Related]
12. Evidence Regarding Pharmacogenetics in Pain Management and Cancer.
Smith DM; Figg WD
Oncologist; 2023 Mar; 28(3):189-192. PubMed ID: 36718020
[TBL] [Abstract][Full Text] [Related]
13. Review of Opioid Pharmacogenetics and Considerations for Pain Management.
Owusu Obeng A; Hamadeh I; Smith M
Pharmacotherapy; 2017 Sep; 37(9):1105-1121. PubMed ID: 28699646
[TBL] [Abstract][Full Text] [Related]
14. Human Genetic Variability Contributes to Postoperative Morphine Consumption.
De Gregori M; Diatchenko L; Ingelmo PM; Napolioni V; Klepstad P; Belfer I; Molinaro V; Garbin G; Ranzani GN; Alberio G; Normanno M; Lovisari F; Somaini M; Govoni S; Mura E; Bugada D; Niebel T; Zorzetto M; De Gregori S; Molinaro M; Fanelli G; Allegri M
J Pain; 2016 May; 17(5):628-36. PubMed ID: 26902643
[TBL] [Abstract][Full Text] [Related]
15. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics.
Saiz-Rodríguez M; Ochoa D; Román M; Zubiaur P; Koller D; Mejía G; Abad-Santos F
Pharmacogenomics; 2020 Jul; 21(10):663-675. PubMed ID: 32538291
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
17. OPRM1 and COMT Gene-Gene Interaction Is Associated With Postoperative Pain and Opioid Consumption After Orthopedic Trauma.
Khalil H; Sereika SM; Dai F; Alexander S; Conley Y; Gruen G; Meng L; Siska P; Tarkin I; Henker R
Biol Res Nurs; 2017 Mar; 19(2):170-179. PubMed ID: 27903758
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics in palliative care.
Kleine-Brueggeney M; Musshoff F; Stuber F; Stamer UM
Forensic Sci Int; 2010 Dec; 203(1-3):63-70. PubMed ID: 20709477
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
20. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GAPJM; Weide JV; Wilffert B; Swen JJ; Guchelaar HJ; Deneer VHM; van Schaik RHN
Eur J Hum Genet; 2022 Oct; 30(10):1105-1113. PubMed ID: 34267337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
